Genetic knockdown and pharmacologic inhibition by the HDAC6 inhibitors markedly reduced melanoma tumor growth and combination therapy further reduced tumor growth compared with the individual effect of either agent and led to a greater infiltration of activated cytotoxic T cells (42). The gene discussed is HDAC6; the disease is melanoma.